Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beauty Of Amgen Bone Drug Results Is In Eye Of The Beholder

This article was originally published in The Pink Sheet Daily

Executive Summary

Top-line results from Phase III bone metastasis prevention trial lift stock price and inspire bullish headlines for Amgen. But vital figures and proof of clinical benefit are missing, making study tougher to interpret.

You may also be interested in...



GTx Estrogen Agonist For Prostate Cancer Looks Effective At Low Doses

On the rebound after venous embolisms led to a clinical hold, Capesaris is getting good results at a significantly lower dose than what was used in that fated trial, and GTx is betting the novel estrogen receptor agonist can improve on the efficacy of androgen deprivation therapy while ameliorating its symptoms.

Radiotherapeutics Market Snapshot: This Sector Is Getting Hot

The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.

New Oncology Indications Should Continue Denosumab’s Upward Trajectory

Already on an upward trajectory in oncology uses, Amgen’s denosumab, known as Prolia and Xgeva, got a bit of a boost with FDA approval of two new indications for treatment-induced bone loss in prostate and breast cancer – though neither is expected to add much to the bottom line.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS071607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel